Back to media

SEED Therapeutics Doses First Patient in Phase 1 Trial of ST-01156, a Molecular Glue Degrader Targeting RBM39

Poster Presentations
January 9, 2025
info@seedtherapeutics.com
411 Swedeland Rd, Suite 1000,
King of Prussia, PA, 19406
HomeTeamOur PipelineMediaOur ScienceContactReferences
© 2026 Seed Therapeutics. All rights reserved.
Privacy PolicyTerms & ConditionsSite by Bunsen